從 2019 年年底，COVID-19 的疫情由中國一路蔓延至全世界，不論是對於人體健康或是社會經濟都造成巨大的衝擊及損害。新冠病毒極強的傳播能力，導致疫情的終結時間難以預測，因此各國無不加緊腳步，投入大量金錢與精力於疫苗的開發，期望藉由疫苗建立起群體免疫，進而控制已於全球造成大流行的 COVID-19 疫情。全球目前有 5 家廠牌之新冠肺炎疫苗具較高的國際通行性，且在歐美等先進國家已陸續上市或是正在美國進行臨床第 3 期試驗，現階段，我國也於 2021 年 3 月 22 日正式開始執行接種計畫。
本篇將以文獻回顧的方式，統整 5 家廠牌疫苗的相關臨床試驗數據，以利更進一步的瞭解新冠肺炎疫苗。

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in China in December 2019. Thereafter, coronavirus disease 2019 (COVID-19) quickly spreads globally, taking a heavy toll on human health and grave damage to society and the economy. Without herd immunity, it is virtually impossible to halt the pandemic due to the highly contagious nature of the disease; thus, developing effective vaccines has become an imminent public health issue. Currently, there are five vaccines in Europe or North America authorized for emergency use or in the third phase of the clinical trial. The first shipment of the COVID-19 vaccine arrived in Taiwan in March 2021.
This review article summarizes data from the clinical trials of the five COVID-19 vaccines to give readers a broad perspective of the tool for containing the unprecedented pandemic.